WOMENS-HEALTH Messages for July, 1998: Re: Endometriosis and Zoladex treatment

Re: Endometriosis and Zoladex treatment

From: anonymous@obgyn.net
Thu, 30 Jul 1998 10:12:21 -0400

Messages sorted by: [ date ][ thread ][ subject ][ author ]
Next message: Terri: "Re: clitoris and surgery"
Previous message: anonymous@obgyn.net: "Re: clitoris and surgery"
In reply to: Soos: "Endometriosis and Zoladex treatment"
Next in thread: Soos: "Re: Endometriosis and Zoladex treatment"
Reply: Soos: "Re: Endometriosis and Zoladex treatment"

At 04:22 98-07-30 -0500, you wrote: >I am a 29 yr old with stage III endo. I have been on Zoladex for a
>month and a half as a precursor to more surgery. I have been concerned
>about what I have read about GnRH antagonists putting women into
>permanent menopause and also whether it permanently damages your
>pituitary glands' ability to receive the hormonal signals, ie it kills
>off the receptors. Is any of this true/likely to happen?
>

Where did you read that? I am not aware of any study about that.

See:[Treatment of pelvic endometriosis with goserelin, an LHRH agonist] [Lecba panevni endometriozy goserelinem, LHRH agonistou.] Ceska Gynekol 1996 Feb;61(1):11-6

To determine the safety and effectiveness of ZOLADEX depot (goserelin) in the therapy of endometriosis

MATERIAL AND METHODS: A multicentric prospective open study of 60 women with endometriosis. R-AFS score of pelvic endomemtriosis was established in patients suffering from pelvalgia, dyspareunia and dysmenorrhoea during pre-treatment laparoscopy. The effect of Zoladex depot applied subcutaneously were evaluated by gynaecological and laboratory examinations, including assessment of subjective complaints every four weeks in the course of six months. Laparoscopic check-up was carried out immediately after terminating the therapy.

RESULTS: (1) The average total score of subjective complaints decreased by 90% after 24 weeks of treatment. (2) Treatment was successful in 67% patients, i.e. laparoscopic examination showed a decrease of the R-AFS score by at least 50%. In 28% treated women visible endometrial foci disappeared completely. (3) The most frequent side-effects of therapy are associated with hypoestrogenic effects of GnRH agonists. Vasomotor instability, flushes and night hyperidrosis occurred in 93% and 90% treated women,respectively.

CONCLUSION: Goserelin acetate is a synthetic GnRH agonist suitable for safe and effective therapy of pelvic endometriosis. The administration of 3.6 mg goserelin every day for 24 weeks reduced markedly the size of endomerial foci and painful symptoms.

Dr Paul-André Latulippe 111 Rang 9 St-Christophe d'Arthabaska Québec,Canada G6P 6S1

andrelat@ivic.qc.ca

tel:(819) 357-1784

Next message: Terri: "Re: clitoris and surgery"
Previous message: anonymous@obgyn.net: "Re: clitoris and surgery"
In reply to: Soos: "Endometriosis and Zoladex treatment"
Next in thread: Soos: "Re: Endometriosis and Zoladex treatment"
Reply: Soos: "Re: Endometriosis and Zoladex treatment"

Women's Insurance Checklist from Auto Insurance Quote

use when must restrict search to only the women's health forum...
Enter search keywords:
	Returns per screen: Require all keywords: